Endoscopic diagnostics and treatment of esophagitis in patients after COVID-19
https://doi.org/10.31146/1682-8658-ecg-213-5-27-33
Abstract
A survey of 65 patients who had undergone COVID-19 and were admitted with a clinical picture of HH, reflux esophagitis was carried out. All patients underwent esophagogastroduodenoscopy, which was diagnosed with reflux esophagitis. According to the Los Angeles classification of esophagitis, grade C was diagnosed in 37 patients (56.9%), grade D in 28 patients (43.1%). In 43 patients (66.2%), there was a pronounced Hp contamination (+++), a moderately pronounced contamination (++) - in 22 patients (33.8%). The inclusion of exogenous nitric oxide in the complex therapy contributed to the eradication of Hp in 93.8% of patients and accelerated the epithelialization of erosions by 2.8-3.1 times compared with patients who did not receive nitric oxide in the complex therapy.
About the Authors
N. E. Chernekhovskaya
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
I. Yu. Korzheva
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation; S. P. Botkin Municipal Clinical Hospital
Russian Federation
Russian Federation
A. V. Volova
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
A. V. Povalyaev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation; Medincentre branch of the GlavUpDK under the MFA of Russia
Russian Federation
Russian Federation
V. G. Andreev
“Alina” LCD
Russian Federation
Russian Federation
References
1. Pan A., Liu L., Wang C., et al. Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China. JAMA. 2020 May 19;323(19):1915-1923. doi: 10.1001/jama.2020.6130.
2. Chen Y., Liu Q., Guo D. Coronaviruses: genome structure, replication, and pathogenesis. J. Med. Virol. 2020;92 (4):418-423.
3. Drapkina O.M., Maev I. V., Bakulin I. G., et al.Interim guidelines: «Diseases of the digestive organs in the context of a new coronavirus infection pandemic (COVID-19)». Profilakticheskaya Meditsina. 2020;23(3):21202152. (In Russ.) doi: 10.17116/profmed202023032120.@@ Драпкина О. М., Маев И. В., Бакулин И. Г. и др. Болезни органов пищеварения в условиях пандемии новой коронавирусной инфекции COVID-19. Временные методические рекомендации. Профилактическая медицина. 2020;23(3):21202152. doi: 10.17116/profmed202023032120.
4. Effenberger M., Grabherr F., Mayr L.et al. Feacal calprotectin indicates intestinal inflammation in COVID-19. Gut. 2020 Aug;69(8):1543-1544. doi: 10.1136/gutjnl-2020-321388.
5. Escher R, Breakey N, Lämmle B. Severe COVID-19 Infection Associated With Endothelial Activation. Thromb Res. 2020 Jun;190:62. doi: 10.1016/j.thromres. 2020.04.014.
6. Varga Z, Flammer AJ, Steiger P, et al. Endothelial Cell Infection and Endotheliitis in COVID-19. Lancet. 2020 May 2;395(10234):1417-1418. doi: 10.1016/S0140-6736 (20)30937-5.
7. Budden K.F., Gellatly S. L., Wood D. L. et al. Emerging pathogenic links between microbiota and the gut lung axis. Nat Rev Microbiol. 2017 Jan;15(1):55-63. doi: 10.1038/nrmicro.2016.142.
8. Sun X., Wang T., Cai D. et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020 Jun;53:38-42. doi: 10.1016/j.cytogfr.2020.04.002.
9. Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017 Jul;39(5):529-539. doi: 10.1007/s00281-017-0629-x.
10. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7.
11. Jin X., Lian J-S., Xu J-H et al. Epidemiological, climical and virological characteristics of 74 cases of coronavirus-infected desease 2019 with gastrointestinal symptoms. Gut. 2020 Jun;69(6):1002-1009. doi: 10.1136/gutjnl-2020-320926.
12. Zhang L., Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol. 2020 May;92(5):479-490. doi: 10.1002/jmv.25707.
13. Maev I. V., Shpektor A. V., Vasileva E. Yu. New coronavirus infection COVID-19: extrapulmonary manifestations. Therapeutic archive. 2020; 92(8):4-11. (in Russ.)@@ Маев И. В., Шпектор А. В., Васильева Е. Ю. и др. Новая коронавирусная инфекция COVID-19: экстрапульмональные проявления. Терапевтический архив. 2020; 92 (8): 4-11.
14. Ong J., Young BE., Ong S. COVID-19 in gastroenterology: a clinical perspective. Gut. 2020 Jun;69(6):1144-1145. doi: 10.1136/gutjnl-2020-321051.
15. Babaev F.A., Babazade D. F. Gastrointestinal complications in patients with COVİD-19. Modern problems of science and education. 2021, No. 4. (in Russ.)@@ Бабаев Ф. А., Бабазаде Д. Ф. Гастроинтестинальные осложнения у больных с COVİD-19 //Современные проблемы науки и образования. - 2021. - № 4.
16. Leung W K., No K. F., Chan R. K. Enteric involvement of severe acute respiratory syndrome associated coronavirus infection. Gastroenterology. 2003 Oct;125(4):1011-7. doi: 10.1016/s0016-5085(03)01215-0.
17. Suresh Kumar V. C., Mukherjee S., Harne P. S. et al. Novelty in the gut: a systematic review and meta-analysis of the gastrointestinal manifestations of COVID-19. BMJ Open Gastroenterol. 2020 May;7(1): e000417. doi: 10.1136/bmjgast-2020-000417.
18. Yandrapu H., Marcinkiewicz M., Sarosiek I. et al. Role of Saliva in Esophageal Defense: Implications in Patients With Nonerosive Reflux Disease. Am J Med Sci. 2015 May;349(5):385-91. doi: 10.1097/MAJ. 0000000000000443.
19. Blevins C.H., Iyer P. G., Vela M. F., Katzka D. A. The Esophageal Epithelial Barrier in Health and Disease. Clin Gastroenterol Hepatol. 2018 May;16(5):608-617. doi: 10.1016/j.cgh.2017.06.035.
20. Ivashkin V.T., Trukhmanov A. S., Gonik M. I. The use of rebamipide in the treatment of gastroesophageal reflux disease. Terapevticheskiy arkhiv. 2020; 92(4):98-104. (in Russ.)@@ Ивашкин В. Т., Трухманов А. С., Гоник М. И. Применение ребамипида в лечении гастроэзофагеальной рефлюксной болезни. Терапевтический архив. 2020; 92(4):98-104.
21. Lazebnik L.B., Tkachenko E. I., Abdulganiyeva D. I. et al. VI National Guidelines For The Diagnosis And Treatment Of Acid-Related And Helicobacter Pylori-Associated Diseases (VI Moscow agreement). Experimental and Clinical Gastroenterology. 2017;(2):3-21. (In Russ.)@@ Лазебник Л. Б., Ткаченко Е. И., Абдулганиева Д. И. и соавт. VI Национальные рекомендации по диагностике и лечению кислотозависимых и ассоциированных с Hp заболеваний. Экспериментальная и клиническая гастроэнтерология. 2017;138 (2):3-21.
22. Ignarro L. J. Physiology and pathophysiology of nitric oxide. Kidney Int Suppl. 1996 Jun;55: S2-5. PMID: 8743501.
23. Arzamassev A.P., Severina I. S., Grigoriev N. B., etc. Exogenous nitric oxide donors and NO-synthase inhibitors (chemical aspect). Vestn. RAMS. 2003;(12):88-95. (in Russ.)@@ Арзамасцев А. П., Северина И. С., Григорьев Н. Б. и др. Экзогенные доноры оксида азота и ингибиторы NO-синтаз (химический аспект) // Вестн. РАМН. - 2003. - № 12. - С. 88-95.
24. Severin E.S., Muizhnek E. L., Severin S. E. The concept of secondary messengers: from fundamentals to clinical practice. Moscow. Dimitrea Graph Group. 2005. 336 p. (in Russ.)@@ Северин Е. С., Муйжнек Е. Л., Северин С. Е. Концепция вторичных мессенджеров: от фундаментальных основ к клинической практике. М.: Димитреа График Групп. 2005. 336 с.
25. Paltzev M.A., Ivanov A. A., Severin S. E.Intercellular interactions. Moscow. Medicine. 2003. 288 p. (in Russ.)@@ Пальцев М. А. Межклеточные взаимодействия/ М. А. Пальцев, А. А. Иванов, С. Е. Северин// М.: Медицина. - 2003. - 288 с.
26. Efimenko N. A. Guidelines for the use of the apparatus “Plazon” in a surgical clinic. Moscow. FGPU “Shcherbinsk Printing House. 2003. 96 p. (in Russ.)@@ Руководство по применению аппарата «Плазон» в хирургической клинике//Под ред. Н. А. Ефименко. - М.: ФГПУ «Щербинская типография. - 2003. - 96 с.
27. Granik V.G., Grigoriev N. B. Nitric oxide (NO). Moscow. University Book. 2004. 359 p. (in Russ.)@@ Граник В. Г., Григорьев Н. Б. Оксид азота (NO). - М.: Вузовская книга. - 2004. - 359 с.
28. Golikov P. P. Nitric oxide in the clinic of urgent diseases. Moscow. MEDPRAKTIKA-M. 2004. 179 p. (in Russ.)@@ Голиков П. П. Оксид азота в клинике неотложных заболеваний. - М.: МЕДПРАКТИКА-М. - 2004. - 179 с.
29. Vanin A.F., Pekshev A. V., Vaganov A. B. Nitric oxide gas and iron dinitrosyl complexes with thiol-containing ligands as putative drugs that can stop COVID-19. Biophysics. 2021;66(1):183-194. (in Russ.)@@ Ванин А. Ф., Пекшев А. В., Ваганов А. Б. и др. Газообразный оксид азота и динитрозильные комплексы железа с тиолсодержащими лигандами как предполагаемые лекарственные средства, способные купировать COVID-19. // Биофизика. - 2021. - Т. 66. - № 1. - С. 183-194.
30. Chernekhovskaya N. E., Hivrenko L. A., Andreev V. G., Pekshev A. V., Povalyaev A. V., Stepanova V. V. Nitric oxide in the complex treatment and prevention of complications in COVID-19. Hospital medicine. 2022;5(4): 41-45. (in Russ.)@@ Чернеховская Н. Е., Хивренко Л. А., Андреев В. Г. и др. Оксид азота в комплексном лечении и профилактике осложнений при COVID-19. // Госпитальная медицина. - 2022. - Т. 5. - № 4. - С. 41-45.
31. Lundell L, Dent J, Bennett J, et al. Endoscopic assessment of esophagitis: clinical and functional correlates and further validation of Los Angeles classification. Gut. 1999 Aug;45(2):172-80. doi: 10.1136/gut.45.2.172.
32. Chernekhovskaya N.E., Shishlo V. K., Chomaeva A. A. Endothelium of blood and lymphatic vessels. Moscow. Institute of Animal Husbandry. 2010, 182 p. (in Russ.)@@ Чернеховская Н. Е., Шишло В. К., Чомаева А. А. Эндотелий кровеносных и лимфатических сосудов. - М.: ВНИИ животноводства. - 2010. - 182 с.
Review
For citations:
Chernekhovskaya N.E., Korzheva I.Yu., Volova A.V., Povalyaev A.V., Andreev V.G. Endoscopic diagnostics and treatment of esophagitis in patients after COVID-19. Experimental and Clinical Gastroenterology. 2023;(5):27-33. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-213-5-27-33
Views:
123
Email this article 